The FDA has cleared PhAST Corp’s PhAST BC GN Panel, an automated phenotypic AST system that delivers antimicrobial susceptibility results from positive blood cultures in as little as 99 minutes.
New research indicates that standard and modified two-tiered testing algorithms fail to detect infection in up to 78% of patients during the early stages of the disease.
A proof-of-concept study shows that bacteria-metabolized molecules enriched with carbon-13 produce detectable exhaled CO2, enabling rapid infection identification with inexpensive infrared scanners.
The July 2024 Tech Guide in Clinical Lab Products features product listings from Affinity Biosensors, Diasorin, DNA Electronics, and Randox.
Avails Medical, a developer of antibiotic susceptibility testing tech, received 510(k) clearance from the U.S. FDA for its new eQUANT system.
COPAN Diagnostics' new colony selection software—PhenoMATRIX TAG—automatically chooses isolated colonies on plated media for picking.
Hardy Diagnostics unveiled a chromogenic biplate designed to help detect and identify CRE and ESBL producing bacteria.